犬用疫苗市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、疾病類型、給藥途徑、成分、地區和競爭格局分類，2021-2031年）

全球犬用疫苗市場預計將從2025年的30.6億美元成長到2031年的45.7億美元，複合年成長率（CAGR）為6.92%。這些生物製藥對於誘導犬隻對特定病原體產生主動免疫至關重要，能夠有效保護犬隻免受狂犬病、犬細小病毒和犬瘟熱等嚴重的侵害。市場成長的主要驅動力是通用感染疾病發病率的上升以及寵物飼主日益重視預防性獸醫護理。寵物人性化趨勢的興起進一步推動了這一成長勢頭，飼主更加重視高品質的醫療保健。根據英國寵物食品協會的數據，英國犬隻數量預計將在2024年達到1,350萬隻，這將顯著推動對動物健康和公共衛生所需疫苗產品的需求。

儘管有這些促進因素，低溫運輸倉儲物流的複雜性仍構成市場發展的重大障礙。運輸和配送過程中嚴格的溫度控制要求增加了營運成本，並限制了基礎設施薄弱地區的產品供應，從而阻礙了市場的進一步擴張。確保整個供應鏈中精確的溫度條件的嚴格要求會增加成本並降低可及性，這對該行業的全球擴張構成重大挑戰。

市場促進因素

動物醫療保健成本的不斷上漲以及寵物人性化趨勢的日益加深是推動市場成長的關鍵因素。飼主越來越將狗視為家庭成員，並認為它們理應享有與人類同等的醫療保健標準，這顯著擴大了對高品質疫苗產品的需求。產業數據也印證了這一投資觀點。根據美國寵物產品協會發布的《2025年產業趨勢報告》，預計到2024年，美國寵物產業的總支出將達到創紀錄的1,520億美元。這筆巨額資金的流入確保了獸醫服務和先進疫苗接種通訊協定的持續資金支持。碩騰公司（Zoetis）的業績也印證了這個趨勢。該公司公佈的2025年第三季營收為24億美元，主要得益於其伴侶動物產品組合的成長。

此外，通用和犬類感染疾病的日益普及感染疾病亟需嚴格執行疫苗接種規定和快速反應措施的關鍵因素。狂犬病等持續存在的威脅不斷給公共衛生系統帶來壓力，促使各國政府實施嚴格的疫苗接種計劃，以維持群體免疫並防止跨物種傳播。美國動物醫院協會 (AAHA) 於 2025 年 9 月發布的流行病學數據顯示，目前美國20 個州正在追蹤 14 起疑似狂犬病疫情，凸顯了這一問題的迫切性。疫情的再次爆發促使人們迅速部署預防方案，並強調了疫苗在保護動物福利和人類安全方面發揮的關鍵作用。

市場挑戰

低溫運輸倉儲的物流複雜性是全球犬用疫苗市場擴張的一大障礙。犬用疫苗屬於生物製藥，需要從生產設施到給藥點全程嚴格且不間斷地進行溫度控制。在基礎設施薄弱或電力供應不穩定的地區，這種溫度穩定性無法得到保證，加劇產品劣化和效力損失。這種不穩定性迫使生產商不得不投入成本購買昂貴的替代品和專用運輸設備，顯著增加營運成本，並使分銷物流更加複雜。

因此，高成本直接阻礙了市場成長，因為對許多寵物主人來說，疫苗接種費用難以負擔。高成本和分銷困難導致疫苗接種率低下，從而有效地抑制了市場規模。例如，HealthforAnimals發布的《2024年全球趨勢報告》發現，英國約有25%的寵物飼主尚未為他們的狗接種疫苗。這個潛在市場的巨大缺口表明，嚴格的物流要求造成的准入障礙和成本影響如何有效地阻礙了市場滲透和獲利能力。

市場趨勢

隨著重組DNA和mRNA疫苗技術的應用，市場正經歷著一場根本性的變革時期，從傳統的生產方式轉向合成和精準的平台。這種變革使製造商能夠快速開發針對不斷演變的病毒株的疫苗，提高安全性並消除通常會引起局部反應的佐劑。 2024年6月，默克動物保健公司（Merck Animal Health）的Novivac® NXT犬流感H3N2疫苗獲得商業性核准，這是首個基於RNA顆粒技術的犬流感疫苗，證明了這一趨勢的商業可行性。與傳統技術相比，這項創新技術簡化了生產流程，並能更快地應對新出現的病原體變種。

同時，犬類腫瘤治療性疫苗的出現正將該領域從單純的預防轉向積極的疾病管理。這些免疫療法旨在重新訓練犬隻的免疫系統，使其攻擊現有的癌細胞，為常見癌症提供了一種非侵入性的化療替代方案。這些疫苗的治療潛力得到了顯著的臨床進展的支持。根據耶魯大學新聞2024年3月的一篇報導，新型免疫療法疫苗已將患有某些癌症的犬隻的12個月存活率從約35%提高到60%。這些治療方法進展正在開闢一個盈利的市場領域，專門針對老年犬的慢性疾病管理。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球犬用疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（減毒活病毒疫苗、不活化疫苗、其他）
  • 依疾病類型分類（犬瘟熱、犬傳染性呼吸道疾病症候群 (CIRDC)、犬小病毒/細小病毒病、犬鉤端螺旋體病、犬萊姆病、犬傳染性肝炎、犬狂犬病、其他疾病）
  • 給藥途徑（注射、鼻腔、口服）
  • 按成分（聯合疫苗、單一疫苗）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美犬用疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲犬用疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區犬用疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲犬用疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美犬用疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球犬用疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zoetis Inc.
• Bioveta as
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac SA
• Zendal Group
• Elanco Animal Health Incorporated

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Dog Vaccine Market is projected to expand from a valuation of USD 3.06 billion in 2025 to USD 4.57 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.92%. These biological formulations are essential for generating active immunity against specific pathogens, effectively shielding canines from severe conditions such as rabies, parvovirus, and distemper. The market's growth is primarily driven by the increasing incidence of zoonotic diseases and a widening base of pet owners dedicated to preventive veterinary medicine. This momentum is further strengthened by the trend of pet humanization, where owners prioritize high-quality healthcare. Data from UK Pet Food indicates that the dog population in the United Kingdom hit 13.5 million in 2024, a density that significantly boosts the demand for immunization products required for animal health and public safety.

Despite these favorable drivers, the market faces substantial hurdles related to the logistical intricacies of cold chain storage. The necessity of maintaining strict temperature controls during transport and distribution drives up operational costs and restricts product availability in regions with inadequate infrastructure, thereby limiting broader market expansion. The rigorous requirement to ensure precise thermal conditions throughout the supply chain can inflate expenses and impede accessibility, posing a significant challenge to the industry's global reach.

Market Driver

The escalating expenditure on animal healthcare and the deepening trend of pet humanization act as the primary catalysts for market growth. Owners increasingly view dogs as integral family members deserving of healthcare standards comparable to humans, a perspective that significantly amplifies the demand for premium vaccine formulations. This readiness to invest is corroborated by industry data; the American Pet Products Association's "2025 State of the Industry Report" noted that total U.S. pet industry spending reached a record $152 billion in 2024. Such substantial financial injection ensures continuous funding for veterinary services and advanced immunization protocols, a trend further validated by Zoetis, which reported $2.4 billion in revenue for the third quarter of 2025 largely due to its companion animal portfolio's performance.

Additionally, the rising prevalence of zoonotic and canine infectious diseases is a critical driver necessitating strict vaccination mandates and rapid response initiatives. persistent threats like rabies continue to pressure public health systems, compelling governments to enforce rigorous immunization schedules to maintain herd immunity and prevent cross-species transmission. The urgency of this matter is highlighted by recent epidemiological data from the American Animal Hospital Association's September 2025 report, which is currently tracking 14 potential rabies outbreaks across 20 U.S. states. This resurgence accelerates the mobilization of prophylaxis programs and underscores the essential role vaccines play in safeguarding both animal welfare and human safety.

Market Challenge

The logistical complexities of cold chain storage represent a formidable barrier to the expansion of the Global Dog Vaccine Market. Canine vaccines are biologically sensitive products that demand strict, uninterrupted temperature maintenance from the manufacturing facility to the point of administration. In areas with poor infrastructure or unreliable power grids, the inability to guarantee this thermal stability results in significant product spoilage and loss of efficacy. This volatility forces manufacturers to incur costs for expensive replacements and specialized transport equipment, which drastically inflates operational expenses and complicates distribution logistics.

Consequently, these elevated costs directly impede market growth by rendering immunization economically unviable for a large segment of the pet-owning population. The high expense and difficulty of distribution result in lower immunization coverage, effectively capping the market's transaction volume. For instance, a 2024 global trends report by HealthforAnimals revealed that approximately 25% of pet owners in the United Kingdom had not provided a primary course of vaccinations for their dogs. This significant gap in the addressable market illustrates how access barriers and cost implications, driven by rigid logistical requirements, effectively stall market penetration and revenue potential.

Market Trends

The market is undergoing a fundamental shift with the adoption of recombinant DNA and mRNA vaccine technologies, moving away from conventional production methods toward synthetic, high-precision platforms. This evolution enables manufacturers to rapidly develop immunizations for mutating viral strains with enhanced safety, eliminating adjuvants that often cause local reactions. The commercial viability of this trend was confirmed in June 2024, when Merck Animal Health received approval for the first canine influenza vaccine built on RNA-particle technology, known as NOBIVAC(R) NXT Canine Flu H3N2. This innovation streamlines manufacturing processes and allows for a faster response to emerging pathogen variants compared to traditional techniques.

Simultaneously, the emergence of therapeutic vaccines for canine oncology is transforming the sector from a purely preventive landscape into one focused on active disease management. These immunotherapies are designed to retrain the canine immune system to attack existing tumor cells, offering a non-invasive alternative to chemotherapy for high-prevalence cancers. The therapeutic potential of these vaccines is supported by significant clinical progress; a March 2024 article by YaleNews reported that a new immunotherapy vaccine increased 12-month survival rates for dogs with certain cancers from approximately 35% to 60%. As these treatments advance, they open a lucrative market segment targeting chronic disease management in aging dogs.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

Report Scope

In this report, the Global Dog Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dog Vaccine Market, By Type

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Dog Vaccine Market, By Disease Type

• Canine Distemper
• Canine Infectious Respiratory Disease Complex (CIRDC)
• Canine Parvoviruses/ Parvovirus Disease
• Canine Leptospirosis
• Canine Lyme Disease
• Infectious Canine Hepatitis
• Canine Rabies
• Other Diseases

Dog Vaccine Market, By Route of Administration

• Injectable
• Intranasal
• Oral

Dog Vaccine Market, By Component

• Combined Vaccines
• Mono Vaccines

Dog Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dog Vaccine Market.

Available Customizations:

Global Dog Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dog Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.2. By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex (CIRDC), Canine Parvoviruses/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Other Diseases)
  • 5.2.3. By Route of Administration (Injectable, Intranasal, Oral)
  • 5.2.4. By Component (Combined Vaccines, Mono Vaccines)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Dog Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Component
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dog Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Component
  • 6.3.2. Canada Dog Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Component
  • 6.3.3. Mexico Dog Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Component

7. Europe Dog Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Component
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dog Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Component
  • 7.3.2. France Dog Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Component
  • 7.3.3. United Kingdom Dog Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Component
  • 7.3.4. Italy Dog Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Component
  • 7.3.5. Spain Dog Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Component

8. Asia Pacific Dog Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Component
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dog Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Component
  • 8.3.2. India Dog Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Component
  • 8.3.3. Japan Dog Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Component
  • 8.3.4. South Korea Dog Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Component
  • 8.3.5. Australia Dog Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Component

9. Middle East & Africa Dog Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Component
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dog Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Component
  • 9.3.2. UAE Dog Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Component
  • 9.3.3. South Africa Dog Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Component

10. South America Dog Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Component
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dog Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Component
  • 10.3.2. Colombia Dog Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Component
  • 10.3.3. Argentina Dog Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Component

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dog Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bioveta a.s
• 15.3. Hester Biosciences Limited
• 15.4. Boehringer Ingelheim International GmbH
• 15.5. Brilliant Bio Pharma Private Limited
• 15.6. Heska Corporation
• 15.7. Merck & Co., Inc.
• 15.8. Virbac S.A.
• 15.9. Zendal Group
• 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer